



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Istiratumab

<b>Cat. No.:</b>	HY-P99672
<b>CAS No.:</b>	1509928-04-4
<b>Target:</b>	IGF-1R; EGFR
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK; JAK/STAT Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers <sup>[1][2][3]</sup> .								
<b>In Vitro</b>	<p>Istiratumab (500 nM, 24 h) inhibits AKT activation in response to IGF-1 and HRG costimulation in human pancreatic cancer cell lines<sup>[2]</sup>.</p> <p>Istiratumab (500 nM, 24 h) inhibits IGF-1- and HRG-induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS mutations<sup>[2]</sup>.</p> <p>Istiratumab (500 nM, 24 h) induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway<sup>[2]</sup>.</p> <p>Istiratumab (1 <math>\mu</math>M, 60 min) block activation of the PI3K and MAPK signaling cascades in ovarian cancer cell lines<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>AsPC1, BxPC3, Capan2, CFPAC1, etc.</td> </tr> <tr> <td>Concentration:</td> <td>500 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.</td> </tr> </table>	Cell Line:	AsPC1, BxPC3, Capan2, CFPAC1, etc.	Concentration:	500 nM	Incubation Time:	24 h	Result:	Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.
Cell Line:	AsPC1, BxPC3, Capan2, CFPAC1, etc.								
Concentration:	500 nM								
Incubation Time:	24 h								
Result:	Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.								

### REFERENCES

- [1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). *Ann Oncol.* 2020 Jan;31(1):79-87.
- [2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. *Clin Cancer Res.* 2018 Jun 15;24(12):2873-2885.
- [3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. *Sci Rep.* 2019 Nov 14;9(1):16832.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA